Search the Newsreel

Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference

GRCE Q2 2026 Earnings: EPS Surprise of 74.42% Overshadowed by 1.82% Share Decline - Financial Health Score

Grace Therapeutics Files for Resale of Up to 4.8 Million Shares

Grace (GRCE) Quarterly Results: EPS Lands Above Forecast at the Close; Post-Earnings: The Stock Ends Up 2.80% in the Latest Session - Core Business Growth

Grace (GRCE) Quarterly Results: EPS Lands Above Forecast at the Close; Post-Earnings: The Stock Ends Up 2.80% in the Latest Session - Non-GAAP Earnings

Grace (GRCE) Earnings Reading: EPS Exceeds Its Estimate in Latest Trading; Price Move: Shares Move 2.80% Higher

Grace (GRCE) Earnings Reading: EPS Exceeds Its Estimate in Latest Trading; Price Move: Shares Move 2.80% Higher - Cash Flow Report

Grace (GRCE) Earnings Reading: EPS Exceeds Its Estimate in Latest Trading; Price Move: Shares Move 2.80% Higher - Profit Margin Analysis

Grace (GRCE) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison at the Close; Trading Response: Shares Finish 1.88% Higher in the Latest Reading - Revenue Per Share

Grace (GRCE) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison at the Close; Trading Response: Shares Finish 1.88% Higher in the Latest Reading - Tech Earnings Analysis

Grace Therapeutics (GRCE) holder lifts indirect stake to 2.76M shares

Grace Therapeutics (GRCE) investor group reports 6.75% stake via convertibles

Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update

Grace Therapeutics (GRCE) books $13.5M R&D impairment, extends cash runway to 2028

Grace Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026

GRCE Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 74.42% EPS Surprise - Management Guidance Update

Grace Therapeutics (GRCE) completes $9.99M Rule 506(b) private equity raise

GRCE Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers a 74.42% Surprise Despite No Revenue - Guidance vs Actual

Grace Therapeutics, Inc. Revenue Breakdown – NASDAQ:GRCE

GRCE Q2 2026 Earnings: 74.42% EPS Surprise as Loss Narrows to -$0.06 - SaaS Earnings Trends

GRCE Q2 2026 Earnings: Loss Narrows Sharply as EPS Beats Estimates by 74.4% - Earnings Weakness Phase

Grace Therapeutics (GRCE): Opaleye reports 2.75M-share, 13.07% ownership stake

Grace Therapeutics (GRCE) Raises $10M in Private Placement Amid High Price-to-Sales Valuation

* Grace Therapeutics (GRCE [https://seekingalpha.com/symbol/GRCE]) entered into a securities purchase agreement for a $10M private placement with new and existing fundamental investors. * The company will issue 4.76M common shares at $2.10 per share in an at-the-market private placement under Nasdaq rules. * The …

Grace Therapeutics Expects Funding to Extend Cash Runway Through 2028

GRCE Q2 2026 Earnings: 74.4% EPS Surprise Signals Stronger Cost Discipline - Earnings Per Share

Grace Therapeutics Advances Second U.S. Manufacturing Route for GTx-104

Grace Therapeutics, Inc (GRCE) Valuation: PE, PB & Fair Value Analysis

GRCE Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline - Earnings Per Share